(VIANEWS) – SALMAR (SALM.OL), MONTEA (MONT.BR), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SALMAR (SALM.OL)
41.5% sales growth and 6.75% return on equity
SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming, Sales & Industry, Icelandic Salmon, and SalMar Aker Ocean segments. It is involved in the broodstock, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.
Earnings Per Share
As for profitability, SALMAR has a trailing twelve months EPS of kr6.7.
PE Ratio
SALMAR has a trailing twelve months price to earnings ratio of 75.52. Meaning, the purchaser of the share is investing kr75.52 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.75%.
Yearly Top and Bottom Value
SALMAR’s stock is valued at kr506.00 at 12:20 EST, way below its 52-week high of kr665.00 and way higher than its 52-week low of kr305.00.
Volume
Today’s last reported volume for SALMAR is 59686 which is 74.17% below its average volume of 231094.
Moving Average
SALMAR’s worth is way higher than its 50-day moving average of kr451.90 and way above its 200-day moving average of kr428.02.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 33.7% and positive 5.3% for the next.
More news about SALMAR.
2. MONTEA (MONT.BR)
25.8% sales growth and 6.28% return on equity
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specialises in logistical property in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space they need to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 31/03/2023 the property portfolio represented a total space of 1,889,054 m² spread across 92 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €4.22.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 17.35. Meaning, the purchaser of the share is investing €17.35 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.28%.
Yearly Top and Bottom Value
MONTEA’s stock is valued at €73.20 at 12:20 EST, way under its 52-week high of €92.80 and way higher than its 52-week low of €62.20.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 19, 2023, the estimated forward annual dividend rate is 3.3 and the estimated forward annual dividend yield is 4.53%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MONTEA’s EBITDA is 18.24.
More news about MONTEA.
3. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.22.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 26.07. Meaning, the purchaser of the share is investing kr26.07 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Volume
Today’s last reported volume for NAVAMEDIC is 15091 which is 55.11% below its average volume of 33621.
More news about NAVAMEDIC.
4. MEDISTIM (MEDI.OL)
16.7% sales growth and 31.89% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.33.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 36.33. Meaning, the purchaser of the share is investing kr36.33 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Volume
Today’s last reported volume for MEDISTIM is 15 which is 99.13% below its average volume of 1741.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MEDISTIM’s EBITDA is 114.4.
Sales Growth
MEDISTIM’s sales growth is 15.7% for the current quarter and 16.7% for the next.
More news about MEDISTIM.
5. VOSS VEKSEL OGLAND (VVL.OL)
16% sales growth and 9.14% return on equity
Voss Veksel- og Landmandsbank ASA provides banking products and services to private individuals and companies in Norway. The company offers saving accounts; car and other vehicle, home, small, and construction loans; overdrafts facilities; leasing services; bank guarantees; bank and payment cards; insurance products; and online and mobile banking services. The company was founded in 1843 and is based in Voss, Norway.
Earnings Per Share
As for profitability, VOSS VEKSEL OGLAND has a trailing twelve months EPS of kr26.36.
PE Ratio
VOSS VEKSEL OGLAND has a trailing twelve months price to earnings ratio of 8.19. Meaning, the purchaser of the share is investing kr8.19 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.14%.
Moving Average
VOSS VEKSEL OGLAND’s worth is below its 50-day moving average of kr233.96 and under its 200-day moving average of kr221.18.
Revenue Growth
Year-on-year quarterly revenue growth grew by 44.9%, now sitting on 141.48M for the twelve trailing months.
More news about VOSS VEKSEL OGLAND.
6. SPAREBANKEN ØST (SPOG.OL)
11.3% sales growth and 7.72% return on equity
Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; current account; home mortgage loans; and mortgage loans for new and used cars. It also provides vehicles, houses and contents, boats, and leisure insurance products, as well as life and health insurance products; and shares and funds trading services. In addition, the company buys, sells, and stores cryptocurrencies, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.
Earnings Per Share
As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr5.6.
PE Ratio
SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 8.52. Meaning, the purchaser of the share is investing kr8.52 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.72%.
More news about SPAREBANKEN ØST.
7. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.16.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 138.75. Meaning, the purchaser of the share is investing kr138.75 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
More news about VISTIN PHARMA.
8. SPAREBANKEN MØRE (MORG.OL)
6.5% sales growth and 11.3% return on equity
Sparebanken Møre, together with its subsidiaries, provides banking services for retail and corporate customers in Norway. It operates through Retail and Real Estate Brokerage segments. The company offers services in the areas of financing, deposits and other forms of investments, payment transfers, financial advisory services, asset management, insurance, and real estate brokerage. Sparebanken Møre was founded in 1843 and is headquartered in Ålesund, Norway.
Earnings Per Share
As for profitability, SPAREBANKEN MØRE has a trailing twelve months EPS of kr16.2.
PE Ratio
SPAREBANKEN MØRE has a trailing twelve months price to earnings ratio of 4.71. Meaning, the purchaser of the share is investing kr4.71 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.3%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 38.5% and 0.4%, respectively.
More news about SPAREBANKEN MØRE.
